Beyond Medical Technologies Announces Debt Repayment, Board Addition, and Appointment of Interim CFO
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) has announced three significant developments: First, the company has successfully repaid 68.7% of its outstanding debt by issuing 7.9 million common shares at $0.05 per share to settle $395,000 of debt obligations. Second, Steven McAuley has been appointed to the Board of Directors, bringing decades of experience in corporate governance and operational strategy. Third, Stevenson Ty has been named Interim Chief Financial Officer, replacing Jatin Baski. Ty brings extensive experience in corporate finance, treasury management, and regulatory compliance from previous executive finance roles.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) ha annunciato tre sviluppi significativi: In primo luogo, l'azienda ha ripagato con successo il 68,7% del suo debito in sospeso emettendo 7,9 milioni di azioni ordinarie a $0,05 per azione per saldare obbligazioni di debito per un totale di $395.000. In secondo luogo, Steven McAuley è stato nominato nel Consiglio di Amministrazione, portando con sé decenni di esperienza nella governance aziendale e nella strategia operativa. Infine, Stevenson Ty è stato nominato Chief Financial Officer ad interim, sostituendo Jatin Baski. Ty vanta una vasta esperienza nella finanza aziendale, nella gestione della tesoreria e nella conformità normativa, proveniente da precedenti ruoli di direzione finanziaria.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) ha anunciado tres desarrollos significativos: Primero, la compañía ha pagado con éxito el 68,7% de su deuda pendiente emitiendo 7,9 millones de acciones comunes a $0,05 por acción para liquidar obligaciones de deuda por un total de $395,000. En segundo lugar, Steven McAuley ha sido nombrado miembro de la Junta Directiva, aportando décadas de experiencia en gobernanza corporativa y estrategia operativa. Por último, Stevenson Ty ha sido nombrado Director Financiero Interino, reemplazando a Jatin Baski. Ty aporta una amplia experiencia en finanzas corporativas, gestión de tesorería y cumplimiento normativo de roles ejecutivos financieros anteriores.
비욘드 메디컬 테크놀로지스 (CSE: DOCT, OTC: DOCKF)가 세 가지 중요한 발전을 발표했습니다: 첫째, 회사는 395,000 달러의 부채 의무를 정산하기 위해 주당 0.05 달러에 790만 주의 보통주를 발행하여 미지급 부채의 68.7%를 성공적으로 상환했습니다. 둘째, 스티븐 맥컬리가 이사회에 임명되어 기업 거버넌스 및 운영 전략에서 수십 년의 경험을 가져왔습니다. 셋째, 스티븐슨 타이가 자틴 바스키를 대신하여 임시 최고 재무 책임자로 임명되었습니다. 타이는 이전의 재무 임원 역할에서 기업 재무, 재무 관리 및 규제 준수에 대한 광범위한 경험을 가지고 있습니다.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) a annoncé trois développements significatifs : Premièrement, la société a réussi à rembourser 68,7 % de sa dette en cours en émettant 7,9 millions d'actions ordinaires à 0,05 $ par action pour régler des obligations de dette d'un montant total de 395 000 $. Deuxièmement, Steven McAuley a été nommé au Conseil d'Administration, apportant des décennies d'expérience en gouvernance d'entreprise et en stratégie opérationnelle. Enfin, Stevenson Ty a été nommé Directeur Financier par intérim, remplaçant Jatin Baski. Ty possède une vaste expérience en finance d'entreprise, en gestion de trésorerie et en conformité réglementaire issue de précédents postes de direction financière.
Beyond Medical Technologies (CSE: DOCT, OTC: DOCKF) hat drei bedeutende Entwicklungen bekannt gegeben: Erstens hat das Unternehmen 68,7 % seiner ausstehenden Schulden erfolgreich beglichen, indem es 7,9 Millionen Stammaktien zu einem Preis von 0,05 $ pro Aktie ausgegeben hat, um Schulden in Höhe von 395.000 $ zu begleichen. Zweitens wurde Steven McAuley in den Vorstand berufen und bringt Jahrzehnte an Erfahrung in der Unternehmensführung und operativen Strategie mit. Drittens wurde Stevenson Ty als Interim Chief Financial Officer benannt, der Jatin Baski ersetzt. Ty bringt umfassende Erfahrung in Unternehmensfinanzierung, Treasury-Management und regulatorischer Compliance aus früheren Positionen im Finanzmanagement mit.
- Significant debt reduction of 68.7% through share issuance
- Strengthened Board of Directors with experienced corporate governance professional
- Appointment of new Interim CFO with extensive financial management experience
- Shareholder dilution due to issuance of 7.9 million new shares
- CFO transition may cause temporary operational disruption
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to announce the successful repayment of
Beyond Medical has completed repayment of
Beyond Medical is also pleased to announce the appointment of Mr. Steven McAuley to its Board of Directors. Mr. McAuley brings decades of experience in corporate governance and operational strategy, further enhancing the Company's leadership team. His appointment aligns with Beyond Medical's commitment to strong governance and strategic growth.
"We are thrilled to welcome Steven McAuley to the Board," said Daniel Liu. "His insights and strategic guidance will be invaluable as we continue to execute on our vision and drive long-term value for our shareholders."
Beyond Medical is further pleased to announce the appointment of Stevenson Ty as Interim Chief Financial Officer, effective immediately. He replaces Jatin Baski, who has stepped down from the role. The Company thanks Mr. Baski for his contributions and wishes him success in his future endeavors.
Stevenson Ty brings extensive experience in corporate finance, treasury management, and regulatory compliance. Prior to joining Beyond Medical, he held executive finance roles at established organizations, leading financial planning and capital management.
"I am excited to join Beyond Medical Technologies at such a pivotal time in its growth," said Stevenson Ty. "I look forward to working with the executive team to drive financial discipline, optimize capital structure, and support the Company's long-term strategic objectives."
Daniel Liu, CEO of Beyond Medical Technologies, added, "We are delighted to welcome Stevenson Ty to the team. His accomplishments as a financial leader with a proven track record in corporate finance will be instrumental as we strengthen our financial position."
About Beyond Medical Technologies Inc.
Beyond Medical Technologies Inc. is a health technology company focused on advancing innovative solutions in the medical and life sciences sectors. The Company is dedicated to improving patient outcomes and operational efficiencies through cutting-edge technology and strategic partnerships.
On behalf of the Board of Directors
Daniel Liu, Chief Executive Officer
Email: danzliu94@gmail.com
https://beyond-md.ca/
Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the accuracy or adequacy of this release.
FORWARD-LOOKING STATEMENTS: This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-Looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-Looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/240750
FAQ
How much debt did Beyond Medical Technologies (DOCKF) repay in February 2025?
What is the share price for Beyond Medical's (DOCKF) debt settlement in 2025?
Who replaced Jatin Baski as CFO of Beyond Medical Technologies (DOCKF)?
How many new shares did Beyond Medical (DOCKF) issue for debt settlement?
